Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

meta-Directing Deactivators: –NO2, –CN, –CHO, –&NoBreak;CO2R, –COR, –CO2H

meta-Directing Deactivators: –NO₂, –CN, –CHO, –⁠CO₂R, –COR, –CO₂H

All meta-directing substituents are deactivating groups. These substituents withdraw electrons from the aromatic ring, making the ring less reactive toward electrophilic substitution. For example, the nitration of nitrobenzene is 100,000 times slower than that of benzene because of the deactivating effect of the nitro group. The first step in an electrophilic aromatic substitution is the addition of an electrophile to form a resonance-stabilized carbocation. The energy diagrams for the...

Preparation of Amines: Reduction of Oximes and Nitro Compounds

Preparation of Amines: Reduction of Oximes and Nitro Compounds

Oximes can be reduced to primary amines using catalytic hydrogenation, hydride reduction, or sodium metal reduction. The reduction of aliphatic and aromatic nitro compounds to primary amines takes place by either catalytic hydrogenation or by using active metals like Fe, Zn, and Sn in the presence of an acid.
Though catalytic hydrogenation can reduce nitrobenzenes, the reduction is nonselective in the presence of other functional groups. For instance, if nitrobenzene contains an aldehyde group,...

Nitric Oxide Signaling Pathway

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Endothelial dysfunction induced by hydroxyl radicals - the hidden face of biodegradable Fe-based materials for coronary stents.

Materials science & engineering. C, Materials for biological applications·2020

Same author

Acidosis-induced metabolic reprogramming in tumor cells enhances the anti-proliferative activity of the PDK inhibitor dichloroacetate.

Cancer letters·2019

Same author

Cancer heterogeneity is not compatible with one unique cancer cell metabolic map.

Oncogene·2016

Same author

A new ER-specific photosensitizer unravels (1)O2-driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT.

Oncogene·2015

Same author

Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.

Computational and mathematical methods in medicine·2015

Same author

Regulation of calcium channels in smooth muscle: new insights into the role of myosin light chain kinase.

Channels (Austin, Tex.)·2014

Search research articles

Related Experiment Video

Updated: May 14, 2026

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through

O Feron¹, C Dessy, J P Desager

¹Department of Medicine, Unit of Pharmacology and Therapeutics, University of Louvain Medical School, Brussels, Belgium.

|January 4, 2001

Summary

This summary is machine-generated.

Atorvastatin reduces caveolin-1 in endothelial cells, improving nitric oxide (NO) production. This cholesterol-lowering effect helps correct endothelial dysfunction in hypercholesterolemia.

More Related Videos

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements

Published on: July 29, 2021

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

Related Experiment Videos

Last Updated: May 14, 2026

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements

Preparation of Rat Skeletal Muscle Homogenates for Nitrate and Nitrite Measurements

Published on: July 29, 2021

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)

Published on: July 3, 2025

Area of Science:

Cardiovascular Science
Molecular Biology
Pharmacology

Background:

Hypercholesterolemia impairs endothelial nitric oxide (NO)-dependent vasodilation.
Elevated cholesterol in endothelial cells increases caveolin-1, stabilizing an inhibitory complex with endothelial NO synthase (eNOS) and reducing NO release.

Purpose of the Study:

To investigate if atorvastatin modulates caveolin abundance, eNOS activity, and NO release by reducing cellular cholesterol.

Main Methods:

Endothelial cells were treated with varying doses of atorvastatin, with or without LDL cholesterol.
Assessed caveolin-1 and eNOS interaction, eNOS activity, and eNOS/Hsp90 association.

Main Results:

Atorvastatin significantly decreased caveolin-1 expression, irrespective of LDL cholesterol levels.
This reduction led to decreased caveolin-1/eNOS inhibition and restored/potentiated eNOS activity.
Atorvastatin promoted eNOS/Hsp90 interaction, further enhancing eNOS activation.

Conclusions:

Atorvastatin enhances NO production in endothelial cells by reducing caveolin-1 expression.
Inhibiting cholesterol synthesis offers a therapeutic strategy for endothelial dysfunction in hypercholesterolemia.